Stay in touch
Find out how to subscribe to company alerts to receive an email whenever an update is posted
The portfolio was valued at £893m at 30 April 2021
We have exposure to over 600 underlying companies, of which the Top 30 contribute 46% of the Portfolio value and 220 companies represent 90% of the Portfolio value. The Portfolio is broadly diversified by sector and geography. This strikes an appropriate balance between concentration, so that Direct Investments can meaningfully impact performance, and diversification, so that we are not overly exposed to the risks of individual portfolio companies or sectors.
Focus on mid-market and large companies
The Portfolio is weighted towards the mid-market (34%) and large deals (56%), which we view as more defensive than smaller deal sizes, benefiting from stronger management teams and often market leading positions.
Portfolio by investment type %
Focus on developed markets
The Portfolio is focused on developed private equity markets, invested across the US (40%), continental Europe (35%) and the UK (18%). In line with one of our strategic objectives, our weighting to the US has increased from 14% at the time of moving to ICG in 2016. Over the same period, the UK weighting has reduced from 45%.
Portfolio by geography %
Focus on sectors with defensive growth characteristics
The Portfolio is well diversified and weighted towards sectors with defensive growth characteristics. Technology (17%), Healthcare (19%), Business Services (12%) and Education (7%) make up 55% of the Portfolio and are particularly attractive sectors. Within our exposure to the Consumer and Industrial sectors (25% and 8% respectively), we have a bias to companies with more defensive business models, non-cyclical growth drivers and high recurring revenue streams. We have low exposure to the Leisure (3%) and Financials (5%) sectors.
Portfolio by sector %
|Consumer goods and services||25.0|
We do not invest in publicly quoted companies but gain listed investment exposure when IPOs are used to exit an investment. In these cases, exit timing typically lies with the third party manager we have invested alongside. We therefore have exposure to listed businesses within our Portfolio.
At 30 April 2021, we had 42 investments in quoted companies, representing 14.3% of the Portfolio value compared to 20.4% at 31 January 2021. The reduction was largely driven by the sale of our entire stake in Telos during February, as well as by the reduction in Chewy’s share price.
During the quarter Signify Health listed on the NYSE and therefore became a quoted company within our Portfolio. It now represents 0.5% of our Portfolio by value. The company provides technology-enabled healthcare payor services, and we have exposure through our investment via New Mountain V
At 30 April 2021 there were three quoted investments that individually accounted for 0.5% or more of the Portfolio value:
|Company||Ticker||% value of Portfolio|
|1||* Chewy (part of PetSmart)||CHWY-US||8.2%|
* % value of Portfolio includes entire holding of PetSmart and Chewy. Majority of value is within Chewy
** Company listed during the financial year